February 6th 2020 - Press notes
The company, founded today, is backed by IMIM and UPF and is developing products and services based on the DisGeNET platform, one of the tools on the genetics of diseases with most information in the world.
23rd August, 2019 - Press notes
Preliminary results from a clinical trial led by the Hospital del Mar Medical Research Institute and Hospital del Mar show a good response to the drug in patients with metastatic tumours that did not respond to the usual treatment. It involves an inhibitor of a dual protein, mTORC1/2, which is key in tumour growth. The researchers had already demonstrated its effectiveness in in vitro and mouse models, in a study published in the journal Molecular Cancer Research.
10 July, 2019 - Press notes
Researchers from the Hospital del Mar Medical Research Institute have been able to prevent the growth of tumours and eliminate them using a treatment that combines chemotherapy with a protein inhibitor to prevent the repair of damaged DNA in cancer cells. The feasibility of this approach has been tested in mice, studying the evolution of metastatic colon tumours from human patients. The use of this drug combination will now be studied in human patients. The research has been published in the journal Molecular Cell.
28 June 2019 - Press notes
Study published in Cancer Immunology Research
Ageing of NK lymphocytes (Natural killer cells) in HER2-positive breast cancer patients can predict the success or failure of targeted treatments. A blood sample is sufficient for detecting this possible resistance biomarker that, if validated, will allow the therapy to be adapted when the disease is diagnosed. This is the first study to identify NK lymphocyte ageing as a parameter that may condition their anti-tumour potential.14 March, 2019 - Press notes
Hospital del Mar is the first centre in Spain and one of the first in Europe to use laser technology to treat epilepsy and brain tumours safely, quickly and in a minimally invasive way. So far, three successful operations have been performed on epilepsy sufferers. In just 48 hours, they were discharged and were able to go home. The centre will operate on 10 patients each year using this pioneering technique.
February 22, 2019 - Press notes
Researchers from the Hospital del Mar and Hospital del Mar Medical Research Institute (IMIM) have led a study verifying the importance of the presence of a specific type of lymphocyte in the success of anti-tumour treatments in patients with HER2-positive breast cancer.
This is the first time that the role of these immune system cells in treatment response has been verified with patient samples. The role HLA molecules play in obtaining good results has also been determined.
This work leads the way to finding new methods for reinforcing both existing treatments and those in a trial phase, including the possibility of transplanting NK cells from healthy patients into cancer sufferers. The study has been published in the journal Clinical Cancer Research
This site complies with the HONcode standard for trustworthy health information: 
Parc Salut Mar
Passeig Marítim 25-29 Barcelona 08003
See location on Google maps
Phone: 93 248 30 00 · Fax: 93 248 32 54
Information request
© 2006 - 2024 Parc de Salut Mar · Legal notice and Privacy Police | Cookie Policy | Accessibility
